

Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decisionⁱ

Actives substances(s): idasanutlin

Latest Decision number(s): 1) P/0196/2020

Corresponding PIP number(s): 1) EMEA-001489-PIP02-19

If the PIP has been submitted as part of a marketing authorisation application in order to comply with the requirements of Article 7 of the Paediatric Regulation (as a condition of the validation of the respective application) and a marketing authorisation was granted based on this application, then there is a legal obligation to complete that PIP. The same applies if there has been a successful post-authorisation application, where the PIP was included in order to comply with the requirements of Article 8 of the Paediatric Regulation.

Please confirm if any of the above applies:

Yes ☐ No ☒

If yes, it means that based on the Marketing Authorisation obtained at the end of that initial procedure or the successful post-authorisation application, as applicable, you are obliged to complete that PIP. That obligation cannot be cancelled by a unilateral decision, including by withdrawing the MA. Such PIP must be completed, unless it is modified in agreement with the PDCO by removing all outstanding PIP measures or granting a full product-specific waiver instead (upon relevant circumstances in accordance with the Paediatric Regulation). Non-completion of a binding PIP establishes noncompliance with the requirements of the Paediatric Regulation, which the European Medicines Agency has an obligation to report to the European Commission.

Please note that development of the medicinal product above in the following **condition(s)/indication(s)**:

Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue)

☒ has been discontinued

for the following reason(s): (tick all that apply)

- ☐ (possible) lack of efficacy in adults
- ☐ (possible) lack of efficacy in children
- ☐ (possible) unsatisfactory safety profile in adults
- ☐ (possible) unsatisfactory safety profile in children
- ☐ commercial reasons (please specify:)
- ☐ manufacturing / quality problems
- ☐ other regulatory action (please specify:)

☒ other reason (please specify: idasanutlin is unlikely to provide clinically meaningful benefit for paediatric patients with cancer.)

Please add a brief description (max 2000 characters) of the reason(s) for the discontinuation:

Based on a detailed analysis of the efficacy and safety data from the idasanutlin paediatric clinical development program, Roche has concluded that idasanutlin is unlikely to provide additional clinically meaningful benefit to address any unmet needs for paediatric patients with cancer in the context of the current treatment landscape. As a result, Roche has decided to cease all development activities in paediatric cancer indications and to close the overall idasanutlin development programme.

Date: 11 November 2024

Contact for inquiries from interested parties: Roche Registration GmbH

Telephone: +497624142892

Email: global.eu_regulatory_office@roche.com

ⁱ This form will be published to the corresponding decision available on the website of the European Medicines Agency.